Study of the Safety, Tolerability and Efficacy of BCT194 in Healthy Volunteers and Patients With Psoriasis.
NCT00417820
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
BCT194
Sponsor
Novartis